FindTrial
Sign In

PQR309

DRUG7 trials

Sponsors

PIQUR Therapeutics AG

Conditions

Advanced Solid TumorsCancerGlioblastoma MultiformeLymphomaMetastatic Breast CancerNon-Hodgkin LymphomaPrimary Central Nervous System Lymphoma

Phase 1

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
CompletedNCT01940133
PIQUR Therapeutics AGAdvanced Solid Tumors
Start: 2014-01-31End: 2015-12-31Updated: 2017-04-12
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
CompletedNCT02723877
PIQUR Therapeutics AGMetastatic Breast Cancer
Start: 2016-03-28End: 2018-10-03Updated: 2019-03-22

Phase 2

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
CompletedNCT02669511
PIQUR Therapeutics AGPrimary Central Nervous System Lymphoma
Start: 2015-11-12End: 2018-01-12Updated: 2019-07-09
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
TerminatedNCT02850744
PIQUR Therapeutics AGGlioblastoma Multiforme
Start: 2015-07-31End: 2017-11-30Updated: 2018-10-19
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
WithdrawnNCT03120000
PIQUR Therapeutics AGPrimary Central Nervous System Lymphoma
Start: 2017-12-31End: 2019-12-31Updated: 2018-11-16
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
CompletedNCT03127020
PIQUR Therapeutics AGLymphoma, Non-Hodgkin Lymphoma
Start: 2016-06-30Updated: 2019-06-28

Unknown Phase

Thte effect of acid reducing agents on the single dose pharmacokinetics of PQR309 and the absolute bioavailability, safety and tolerability of PQR309 following oral and intravenous administration in healthy subjects.
Active, not recruitingNL-OMON43263
PIQUR Therapeutics AGCancer
Start: 2016-07-22Target: 38Updated: 2024-02-28

Related Papers

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
2019-11-0827 citations
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
2018-04-1351 citations
Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
Cancer Research2017-02-152 citations
Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax
Blood2016-12-02
Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors.
Journal of Clinical Oncology2016-05-203 citations
Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
Molecular Cancer Therapeutics2015-12-01
Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
Cancer Research2015-08-011 citations
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
Journal of Clinical Oncology2015-05-203 citations
The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response
Blood2014-12-062 citations